Avanza Fonder AB Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Avanza Fonder AB acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,977 shares of the medical device company's stock, valued at approximately $3,731,000.

Several other large investors have also added to or reduced their stakes in the stock. Yarbrough Capital LLC bought a new position in DexCom in the 4th quarter valued at $217,000. Carnegie Investment Counsel raised its position in shares of DexCom by 11.0% in the fourth quarter. Carnegie Investment Counsel now owns 3,530 shares of the medical device company's stock worth $275,000 after buying an additional 350 shares in the last quarter. Legacy Wealth Asset Management LLC purchased a new stake in shares of DexCom in the fourth quarter worth $315,000. Hennion & Walsh Asset Management Inc. boosted its stake in DexCom by 17.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 5,163 shares of the medical device company's stock valued at $402,000 after buying an additional 754 shares during the period. Finally, Outlook Wealth Advisors LLC purchased a new position in DexCom during the fourth quarter worth about $477,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DXCM shares. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. Wells Fargo & Company lifted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Finally, Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $86.00 to $104.00 in a research report on Thursday. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $99.29.

DexCom Price Performance

DXCM opened at $84.38 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock's 50 day simple moving average is $78.17 and its 200 day simple moving average is $78.22. The firm has a market cap of $32.96 billion, a price-to-earnings ratio of 50.53, a PEG ratio of 2.00 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.